In addition, HER2 amplification has been identified as an acquired resistance mechanism in EGFR-mutant NSCLC cancers treated with EGFR inhibitors, occurring in approximately 15% of patients resistant to EGFR TKIs. Here, ERBB2 is linked to cancer.